On the back of todays announcement, and for a bit of HIGHLY SPECULATIVE fun, I knocked up this ready-reckoner table try to estimate a ball park valuation for Bisantrene, if it was to one day be commonly administered inconjunction with Doxorubicin.
Note my assumptions, please make your own. This is not advice or a prediction, so please treat accordingly.
Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells, page-78
-
- There are more pages in this discussion • 141 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
0.040(2.93%) |
Mkt cap ! $239.3M | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.50 | $1.35 | $167.2K | 118.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3547 | $1.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 2072 | 1 |
View Market Depth
| Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |